147 related articles for article (PubMed ID: 31026719)
1. Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2.
Wei D; Fan H; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Zhang Q; Zeng C; Hu L
Bioorg Chem; 2019 Jul; 88():102916. PubMed ID: 31026719
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors.
Li J; Gu W; Bi X; Li H; Liao C; Liu C; Huang W; Qian H
Bioorg Med Chem; 2017 Dec; 25(24):6674-6679. PubMed ID: 29146452
[TBL] [Abstract][Full Text] [Related]
3. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
4. Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
Shi W; Qiang H; Huang D; Bi X; Huang W; Qian H
Eur J Med Chem; 2018 Oct; 158():814-831. PubMed ID: 30248654
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy.
Zhuo LS; Wu FX; Wang MS; Xu HC; Yang FP; Tian YG; Zhao XE; Ming ZH; Zhu XL; Hao GF; Huang W
Eur J Med Chem; 2020 Dec; 208():112785. PubMed ID: 32898795
[TBL] [Abstract][Full Text] [Related]
6. Design and biological evaluation of 3-substituted quinazoline-2,4(1
Hassan A; Mubarak FAF; Shehadi IA; Mosallam AM; Temairk H; Badr M; Abdelmonsef AH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2189578. PubMed ID: 36919632
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2.
Qiang H; Gu W; Huang D; Shi W; Qiu Q; Dai Y; Huang W; Qian H
Bioorg Med Chem; 2016 Aug; 24(16):3353-8. PubMed ID: 27068889
[TBL] [Abstract][Full Text] [Related]
8. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J
Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H
Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
[No Abstract] [Full Text] [Related]
11. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice.
Fan H; Wei D; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Xu Y; Hu L
Eur J Med Chem; 2019 Aug; 175():349-356. PubMed ID: 31096155
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
15. Selective VEGFR-2 inhibitors: Synthesis of pyridine derivatives, cytotoxicity and apoptosis induction profiling.
AbdelHaleem A; Mansour AO; AbdelKader M; Arafa RK
Bioorg Chem; 2020 Oct; 103():104222. PubMed ID: 32889383
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
18. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.
Nakagawa T; Tohyama O; Yamaguchi A; Matsushima T; Takahashi K; Funasaka S; Shirotori S; Asada M; Obaishi H
Cancer Sci; 2010 Jan; 101(1):210-5. PubMed ID: 19832844
[TBL] [Abstract][Full Text] [Related]
19. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents.
Devegowda PS; Balaji KS; Prasanna DS; Swaroop TR; Kameshwar VH; Jayarama S; Siddalingaiah L; Rangappa KS
Anticancer Agents Med Chem; 2018 Feb; 17(14):1931-1941. PubMed ID: 28403784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]